Dieng, Mbathio
Lord, Sarah J.
Nieweg, Omgo E.
Saw, Robyn P. M.
Einstein, Andrew J.
Nijhuis, Amanda A. G.
Turner, Robin M.
Thompson, John F.
Morton, Rachael L.
Funding for this research was provided by:
Cancer Australia, Priority-driven Collaborative Cancer Research Scheme Grant (#1129568)
University of Sydney, Robinson Fellowship to RLM
National Health and Medical Research Council (1135285, 1150989)
Article History
Received: 26 February 2021
Accepted: 26 February 2021
First Online: 2 May 2021
Disclosures
: John F. Thompson is the recipient of an NHMRC Program Grant (No. 1093017). He has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK, and Provectus Inc, and travel support from GSK and Provectus Inc. Robyn P. M. Saw served on the - Advisory Board for Novartis, MSD, and Qbiotics and received speaking honoraria from BMS. Andrew Einstein reported receiving grant funding to Columbia University for unrelated research from the National Heart Lung, and Blood Institute, the National Cancer Institute, the International Atomic Energy Agency, Canon Medical Systems, GE Healthcare, Roche Diagnostics, and W. L. Gore & Associates and consulting and lecturing fees from Ionetix and W. L. Gore & Associates.